Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.30 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
| ▸ | INPP5B | P32019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144605 | 0.84 | FDPS (0.50) | FDPSBLMTDP1CA2BTN3A1 | |
| SCHEMBL17323855 | 0.82 | FDPS (0.47) | FDPSBLMTDP1CA2BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL3787748 | 0.81 | FDPS (0.91) | FDPSBLMTDP1CA2BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL30812364 | 0.81 | FDPS (0.91) | FDPSBLMTDP1CA2BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL29461493 | 0.81 | FDPS (0.91) | FDPSBLMTDP1CA2BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL2387461 | 0.81 | FDPS (0.91) | FDPSBLMTDP1CA2BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL378580 | 0.81 | FDPS (0.91) | FDPSBLMTDP1CA2BTN3A1 | |
| SCHEMBL14870920 | 0.79 | — | — | |
| SCHEMBL2045368 | 0.79 | — | — | |
| SCHEMBL16286118 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10994025-B2 | Argonaute protein-double stranded RNA complexes and uses related thereto | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-05-04 | — | — | US | claimed |
| US-20180326092-A1 | ARGONAUTE PROTEIN-DOUBLE STRANDED RNA COMPLEXES AND USES RELATED THERETO | UNITED STATES GOVERNMENT | 2018-11-15 | — | — | US | claimed |
| WO-2018209288-A1 | ARGONAUTE PROTEIN-DOUBLE STRANDED RNA COMPLEXES AND USES RELATED THERETO | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-11-15 | — | — | WO | claimed |
| EP-2325193-A2 | Methods and compositions for therapeutic use of RNA interference | Insert Therapeutics, Inc. (US) | 2011-05-25 | — | — | EP | claimed |
| EP-2134375-A2 | piRNA AND USES RELATED THERETO | COLD SPRING HARBOR LABORATORY (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090062228-A1 | piRNA and uses related thereto | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-03-05 | — | — | US | claimed |
| WO-2008109142-A2 | PIRNA AND USES RELATED THERETO | COLD SPRING HARBOR LABORATORY (US) | 2008-09-12 | — | — | WO | claimed |
| CN-100384865-C | Methods and compositions for therapeutic use of RNA interference | INSERT THERAPEUTICS INC (US) | 2008-04-30 | — | — | CN | claimed |
| EP-1575976-A4 | METHODS AND COMPOSITIONS FOR THERAPEUTIC USE OF RNA INTERFERENCE | INSERT THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| CN-1771255-A | Methods and compositions for therapeutic use of RNA interference | INSERT THERAPEUTICS INC (US) | 2006-05-10 | — | — | CN | claimed |
| EP-1575976-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC USE OF RNA INTERFERENCE | Insert Therapeutics Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004033620-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC USE OF RNA INTERFERENCE | INSERT THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040063654-A1 | Methods and compositions for therapeutic use of RNA interference | INSERT THERAPEUTICS, INC. | 2004-04-01 | — | — | US | claimed |
| US-20030157030-A1 | Controlling expression of target genes; anticancer agents, vascular disorders, central nervous system disorders, antiinflamamtory aagents, autoimmune disease | INSERT THERAPEUTICS, INC. (US) | 2003-08-21 | — | — | US | claimed |
| CN-111356764-B | Compositions and methods for reducing serum cholesterol and PCSK9 | 卡斯西部储备大学 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024059335-A1 | METHODS OF TREATING AGE-RELATED AND INHERITED RETINAL DYSFUNCTIONS | UNIVERSITY OF CALIFORNIA - IRVINE (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230159629-A1 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| WO-2001087934-A2 | TREATMENT OF NEOPLASIA/TRANSFORMATION USING A PITUITARY TUMOR TRANSFORMING GENE CARBOXY TERMINAL PEPTIDES | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001088116-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087935-A2 | METHODS OF MODULATING ANGIOGENESIS BY REGULATING THE EXPRESSION OF PITUITARY TUMOR TRANSFORMING GENE (PTTG) | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063654-A1 | Methods and compositions for therapeutic use of RNA interference | EIF2AK2, SNRPE, RNMT | FDPS 4192/4885BLM 1819/4885TDP1 1126/4885 |
| US-10994025-B2 | Argonaute protein-double stranded RNA complexes and uses related thereto | AGO2, MTREX, SNRPE | FDPS 2143/4885BLM 1696/4885TDP1 1115/4885 |
| US-20030157030-A1 | Controlling expression of target genes; anticancer agents, vascular disorders, central nervous system disorders, antiinflamamtory aagents, autoimmune disease | EIF2AK2, SNRPE, RNMT | FDPS 4213/4885BLM 1793/4885TDP1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.